precision ECG

We use ERT’s High Precision QT methodology to do Expert Precision QT (EPQT)

  • 10-fold more data points than current semi-automated methods
  • Higher quality QRST complexes; very low data variability
  • Greater precision, hence more cost-effective drug development
  • Fewer false positive and inconclusive results
  • Potential waiver of the later stage, mandatory and costly ($2–5 million) TQT trials
  • Informed decision-making process across the entire drug development portfolio
  • EPQT is supported by a global consortium of regulators and pharma companies
  • Recommended analysis includes Method Bias Sensitivity (MBS)  
  • MBS analysis gives regulators certainty that the ECG core lab hasn’t introduced bias into the test results